OTLK Outlook Therapeutics Inc

Price (delayed)

$0.6617

Market cap

$161.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.77

Enterprise value

$168.28M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 18
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is ...

Highlights
Outlook Therapeutics's equity has surged by 72% YoY and by 64% QoQ
The quick ratio has soared by 67% since the previous quarter and by 32% year-on-year
The EPS has contracted by 35% YoY but it has grown by 34% from the previous quarter
The revenue has shrunk by 177% YoY
Outlook Therapeutics's gross profit has shrunk by 89% QoQ

Key stats

What are the main financial stats of OTLK

OTLK stock price

How has the Outlook Therapeutics stock price performed over time
Intraday
-4.96%
1 week
-2.25%
1 month
2.24%
1 year
-31.87%
YTD
-58.12%
QTD
-58.38%

Financial performance

How have Outlook Therapeutics's revenue and profit performed over time
Revenue
-$1.16M
Gross profit
-$2.28M
Operating income
-$55.64M
Net income
-$61.12M
Gross margin
N/A
Net margin
N/A
The revenue has shrunk by 177% YoY
Outlook Therapeutics's gross profit has shrunk by 89% QoQ
The net income has contracted by 41% YoY
OTLK's operating income is up by 23% YoY and by 8% QoQ

Price vs fundamentals

How does OTLK's price correlate with its fundamentals

Growth

What is Outlook Therapeutics's growth rate over time

Valuation

What is Outlook Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 35% YoY but it has grown by 34% from the previous quarter
Outlook Therapeutics's equity has surged by 72% YoY and by 64% QoQ
The revenue has shrunk by 177% YoY

Efficiency

How efficient is Outlook Therapeutics business performance
The company's return on assets fell by 45% YoY but it rose by 4.2% QoQ

Dividends

What is OTLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OTLK.

Financial health

How did Outlook Therapeutics financials performed over time
OTLK's total assets is 28% smaller than its total liabilities
The quick ratio has soared by 67% since the previous quarter and by 32% year-on-year
The current ratio has soared by 50% from the previous quarter and by 21% YoY
OTLK's debt to equity has dropped by 90% year-on-year and by 88% since the previous quarter
Outlook Therapeutics's equity has surged by 72% YoY and by 64% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.